TSX higher on employment data
Investing.com - Truist Securities maintained its Buy rating and $459.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY), which has seen its stock surge nearly 90% year-to-date and currently trades near its 52-week high of $469.81, following the presentation of KARDIA3 trial data at ESC 2025. According to InvestingPro data, the company maintains a strong financial health score and has received positive earnings revisions from 13 analysts.
The research firm noted that Alnylam presented topline data for Cohort A of the Phase 2 KARDIA3 trial with zilebesiran and announced details of the planned Phase 3 cardiovascular outcomes trial (CVOT) over the weekend at ESC 2025.
Truist Securities characterized the blood pressure lowering effects of zilebesiran on top of multiple background antihypertensive agents as modest, with efficacy of approximately 6.6 mmHg in the pre-specified group of patients on background diuretics with blood pressure ≥140 mmHg.
The firm pointed out that other emerging antihypertension drugs with novel mechanisms of action, including baxdrostat and lorundrostat, have demonstrated more robust efficacy than observed with zilebesiran.
Truist Securities does not view the KARDIA3 data as substantially de-risking for zilebesiran and is keeping the opportunity as upside to its model, noting that the CVOT trial will not readout for several years.
In other recent news, Alnylam Pharmaceuticals reported impressive sales figures for its Amvuttra treatment, generating approximately $150 million in its first full quarter for ATTR-CM, significantly surpassing Oppenheimer’s estimate of $10 million and the consensus forecast of $17 million. This strong sales performance led Oppenheimer to upgrade Alnylam’s stock from Perform to Outperform, setting a price target of $490.00. Piper Sandler has also reiterated an Overweight rating with a $449.00 price target, following positive 48-month follow-up data from the Phase III HELIOS-B trial, which showed AMVUTTRA reduced the risk of all-cause mortality or cardiovascular events by 37%. Truist Securities maintained its Buy rating and a $459.00 price target, anticipating upcoming clinical data presentations. Wolfe Research upgraded Alnylam from Underperform to Peerperform, noting better-than-expected patient acquisition capabilities. These developments highlight the company’s recent momentum in both clinical performance and market uptake.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.